19 research outputs found
Distribution of bleeding events of patients on triple therapy by bleeding site.
<p>Distribution of bleeding events of patients on triple therapy by bleeding site.</p
Screening algorithm of patients on triple therapy after stent implantation.
<p>A total of 24892 patients were treated within 2000 and 2012. A computerized search returned 1244 hits of which 213 were actually discharged on triple therapy. Complete data is available on 138 patients.</p
Distribution of the CHA<sub>2</sub>DS<sub>2</sub>-VASc and the HAS-BLED Score of all patients on triple therapy.
<p>Distribution of the CHA<sub>2</sub>DS<sub>2</sub>-VASc and the HAS-BLED Score of all patients on triple therapy.</p
Number of patients discharged on triple therapy by year.
<p>Number of patients discharged on triple therapy by year.</p
Distribution of proton pump inhibitor usage of all patients and of patients with bleeding events.
<p>PPI: proton pump inhibitor.</p
Transfusions of platelets, red blood cells and fresh frozen plasma; Percentage of patients requiring any transfusion (A), Average number of transfused blood products in all patients (B), Average number of transfused blood products in patients receiving at least one transfusion (C).
<p>Transfusions of platelets, red blood cells and fresh frozen plasma; Percentage of patients requiring any transfusion (A), Average number of transfused blood products in all patients (B), Average number of transfused blood products in patients receiving at least one transfusion (C).</p
Bleeding incidence on venoarterial extracorporeal membrane oxygenation therapy, bleeding incidence during venoarterial extracorporeal membrane oxygenation therapy is given as percentage of patients with bleeding to total patients treated.
<p>Bleeding incidence on venoarterial extracorporeal membrane oxygenation therapy, bleeding incidence during venoarterial extracorporeal membrane oxygenation therapy is given as percentage of patients with bleeding to total patients treated.</p
Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation
<div><p>Aims</p><p>Bleeding is a frequent complication in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO). An indication for dual antiplatelet therapy due to coronary stent implantation is present in a considerable number of these patients. The objective of this retrospective study was to evaluate if dual antiplatelet therapy (DAPT) significantly increases the high intrinsic bleeding risk in patients on VA-ECMO.</p><p>Methods and Results</p><p>A total of 93 patients were treated with VA-ECMO between October 2010 and October 2013. Average time on VA-ECMO was 58.9 ± 1.7 hours. Dual antiplatelet therapy was given to 51.6% of all patients. Any bleeding was recorded in 60.2% of all patients. There was no difference in bleeding incidence in patients on DAPT when compared to those without any antiplatelet therapy including any bleeding (66.7% vs. 57.1%, p = 0.35), BARC3 bleeding (43.8% vs. 33.3%, p = 0.31) or pulmonary bleeding (16.7% vs. 19.0%, p = 0.77). This holds true after adjustment for confounders. Rate of transfusion of red blood cells were similar in patients with or without DAPT (35.4% vs. 28.6%, p = 0.488).</p><p>Conclusions</p><p>Bleeding on VA-ECMO is frequent. This registry recorded no statistical difference in bleeding in patients on dual antiplatelet therapy when compared to no antiplatelet therapy. When indicated, DAPT should not be withheld from VA ECMO patients.</p></div